Literature DB >> 11716814

Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey.

S Lamontagne1, E Meadows, P Luk, D Normandin, E Muise, L Boulet, D J Pon, A Robichaud, G S Robertson, K M Metters, F Nantel.   

Abstract

Pre-clinical and clinical studies are currently underway to evaluate the potential of phosphodiesterase-4 (PDE4) inhibitors for the treatment of chronic obstructive pulmonary disease and other inflammatory conditions of the airways. The most common side effect associated with this class of compounds is emesis. The squirrel monkey provides a model for evaluating the efficacy of PDE4 inhibitors and their emetic potential. The distribution of three PDE4 isoforms (A, C and D) has been investigated in the squirrel monkey medulla and nodose ganglion to determine which isoform(s) could be responsible for the emetic adverse effects. The distribution of PDE4 isoforms was delineated using immunohistochemistry with antibodies specific for PDE4A, PDE4C and PDE4D and by in situ hybridization with isoform-selective riboprobes. PDE4A was present in the medulla where expression was mostly restricted to glial cells and the vasculature. PDE4C was not detected in either the medulla or nodose ganglion. Finally, the PDE4D isoform was localized to neurons in the nodose ganglion and found through many structures of medulla including the area postrema, neurons of the nucleus tractus solitarius and locus coeruleus. These data are consistent with a role for PDE4D in the emetic response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716814     DOI: 10.1016/s0006-8993(01)03023-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  17 in total

Review 1.  PDE4 inhibitors: current status.

Authors:  D Spina
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

Review 2.  PDE4 as a target for cognition enhancement.

Authors:  Wito Richter; Frank S Menniti; Han-Ting Zhang; Marco Conti
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

3.  The novel distribution of phosphodiesterase-4 subtypes within the rat retina.

Authors:  C M Whitaker; N G F Cooper
Journal:  Neuroscience       Date:  2009-07-26       Impact factor: 3.590

4.  GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses.

Authors:  O Bruno; E Fedele; J Prickaerts; L A Parker; E Canepa; C Brullo; A Cavallero; E Gardella; A Balbi; C Domenicotti; E Bollen; H J M Gijselaers; T Vanmierlo; K Erb; C L Limebeer; F Argellati; U M Marinari; M A Pronzato; R Ricciarelli
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

5.  Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior.

Authors:  Rolf T Hansen; Marco Conti; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

6.  Phosphodiesterase 4 inhibitors and drugs of abuse: current knowledge and therapeutic opportunities.

Authors:  Christopher M Olsen; Qing-Song Liu
Journal:  Front Biol (Beijing)       Date:  2016-10-17

Review 7.  Phosphodiesterase 4D: an enzyme to remember.

Authors:  Roberta Ricciarelli; Ernesto Fedele
Journal:  Br J Pharmacol       Date:  2015-09-22       Impact factor: 8.739

Review 8.  PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.

Authors:  Victoria Boswell-Smith; Domenico Spina
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 9.  Evaluation of PDE4 inhibition for COPD.

Authors:  Desuo Wang; Xiangli Cui
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Biological targets for therapeutic interventions in COPD: clinical potential.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Luca Gallelli; Teresa Renda; Mario Caputi; Rosario Maselli; Serafino A Marsico
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.